News & Updates

Vaginal oestrogen: A non-antibiotic way to cut repeat UTI risk in postmenopausal women

21 Jun 2020

Local oestrogen preparations may safely and effectively reduce the number of recurrent urinary tract infections (rUTIs) in with genitourinary syndrome of menopause (GSM), delivering symptomatic relief and hence improving quality of life, according to a review.

Vaginal oestrogen: A non-antibiotic way to cut repeat UTI risk in postmenopausal women

21 Jun 2020

Vapour thermal therapy benefits sustained through 5 years for BPH patients

15 Jun 2020 by

The minimally invasive water vapour thermal therapy significantly reduced symptoms of benign prostatic hyperplasia (BPH), including lower urinary tract symptoms (LUTS) and urinary flow rate, and the improvements were sustained through to 5 years, according to long-term data released during the American Urological Association (AUA) 2020 Virtual Meeting.

Vapour thermal therapy benefits sustained through 5 years for BPH patients

15 Jun 2020

Relugolix a new HERO for prostate cancer patients?

11 Jun 2020 by

The phase III HERO trial presented at ASCO20 Virtual demonstrated the superiority of the GnRH* antagonist relugolix over the LHRH** agonist leuprolide for treating advanced prostate cancer (PCa).

Relugolix a new HERO for prostate cancer patients?

11 Jun 2020

Savolitinib an alternative for MET-driven kidney cancer?

09 Jun 2020 by

The investigational, highly selective MET inhibitor savolitinib demonstrated encouraging efficacy and safety vs standard-of-care sunitinib in patients with MET-driven*, unresectable and locally advanced, or metastatic papillary renal cell carcinoma (PRCC), according to the phase III SAVOIR trial results presented at ASCO 2020.

Savolitinib an alternative for MET-driven kidney cancer?

09 Jun 2020

Circulating tumour cell detection ups risk of biochemical recurrence in prostate cancer

06 Jun 2020

Detection of circulating tumour cells appears to increase the risk of biochemical recurrence in patients with prostate cancer, suggesting that such detection precedes prostate-specific antigen (PSA) risk following surgery in cases of prostate cancer recurrence, reveals a recent study.

Circulating tumour cell detection ups risk of biochemical recurrence in prostate cancer

06 Jun 2020

$Ospemifene effective against vulvovaginal atrophy in women with refractory OAB symptoms$

Ospemifene effective against vulvovaginal atrophy in women with refractory OAB symptoms

27 May 2020

Ospemifene appears to produce significant improvements in bladder wall thickness and vaginal dryness, as well as reductions in the number of episodes of nocturia and urgency, among others, in women with vulvovaginal atrophy (VVA) and overactive bladder (OAB) symptoms refractory to β3-agonists or antimuscarinic drugs, a study has shown.

Ospemifene effective against vulvovaginal atrophy in women with refractory OAB symptoms

27 May 2020

Cardiovascular risk higher in men with prostate cancer

25 May 2020

About two in three men with prostate cancer are at increased cardiovascular (CV) risk, suggests a recent study. A positive association exists between a plan to use androgen deprivation therapy and baseline CV risk factors, but such link is explained by confounding factors.

Cardiovascular risk higher in men with prostate cancer

25 May 2020

Tamsulosin plus mirabegron proven safe, effective in men with overactive bladder

24 May 2020

Mirabegron add-on therapy is both safe and effective in the treatment of men with overactive bladder symptoms receiving tamsulosin for benign prostatic hyperplasia, according to the results of a randomized, phase IV study.

Tamsulosin plus mirabegron proven safe, effective in men with overactive bladder

24 May 2020

Semen quality not altered by protein supplements

24 May 2020

Protein supplements do not have any effect on semen quality characteristics of healthy men, a study has found.

Semen quality not altered by protein supplements

24 May 2020

Vitamin D supplementation not beneficial for prevention, progression reduction of UI

23 May 2020

Use of oral vitamin D does not result in reduced urgency or mixed urinary incontinence (UI) progression in women, a study reports.

Vitamin D supplementation not beneficial for prevention, progression reduction of UI

23 May 2020

News & Updates

Filter by Specialty:

Specialty:

Vaginal oestrogen: A non-antibiotic way to cut repeat UTI risk in postmenopausal women

Vaginal oestrogen: A non-antibiotic way to cut repeat UTI risk in postmenopausal women

Vapour thermal therapy benefits sustained through 5 years for BPH patients

Vapour thermal therapy benefits sustained through 5 years for BPH patients

Relugolix a new HERO for prostate cancer patients?

Relugolix a new HERO for prostate cancer patients?

Savolitinib an alternative for MET-driven kidney cancer?

Savolitinib an alternative for MET-driven kidney cancer?

Circulating tumour cell detection ups risk of biochemical recurrence in prostate cancer

Circulating tumour cell detection ups risk of biochemical recurrence in prostate cancer

Ospemifene effective against vulvovaginal atrophy in women with refractory OAB symptoms

Ospemifene effective against vulvovaginal atrophy in women with refractory OAB symptoms

Cardiovascular risk higher in men with prostate cancer

Cardiovascular risk higher in men with prostate cancer

Tamsulosin plus mirabegron proven safe, effective in men with overactive bladder

Tamsulosin plus mirabegron proven safe, effective in men with overactive bladder

Semen quality not altered by protein supplements

Semen quality not altered by protein supplements

Vitamin D supplementation not beneficial for prevention, progression reduction of UI

Vitamin D supplementation not beneficial for prevention, progression reduction of UI